Systematic Review Of Efficacy And Safety Of Antenata Ambroxol Treatmentfor Prevention Of Infant Respiratory Distress Syndrome

Objective To assess the efficacy and safety of antenatal ambroxol treatment for prevention of infant respiratory distress syndrome.Method:The standard search strategy was made according to the Cochrane systematic review handbook and trials were searched in the PubMED,EMBASE, the Cochrane Central Register of Controlled Trials, OVDI,Chinese CBM, Chinese VIP Database, Chinese Wanfang Database and Chinese CNKI Database for randomezed controlled trials (RCT) or quasi-randomize controlled trials on ambroxol for the antenatal prevention of infant respiratory distress syndrome.We hand-searched several related journals for randomized controlled trials or quasi-randomize controlled trials.We included randomized controlled trials that met the inclusion and exclusion critcria.The quality of the included trials was critically appraised. Data synthesis and analysis was performed with the use of the Cochrane Collaboration's software(RenMan version 5.0).Results:Two trials were included involving 166 patients.The quality assessment for the trials demonstrated as C class.The results of meta-analysis indicated that there were statistical difference on the morbility of newborn respiratory distress syndrome between ambroxol treatment group and control group with RR 0.14,95% CI 0.06 to 0.34.No serious adverse events related to the ambroxol treatment were reported.Conclusion:This systematic review shows that antenatal use of ambroxol can reduce the risk of infant respiratory distress syndrome. However,this systematic review can not draw a conclusion about the effectiveness and safety of antenatal ambroxol in the prevention of infant respiratory distress syndrome due to the poor quantity of included trials.It needs to be further confirmes through more well-designed ,multi-centered, large-sample randomized controlled trials.